# Ultralife Corp: overview ULBI · Nasdaq · CIK 875657 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/ulbi.md) · [Financials](/companies/ulbi/financials.md) · [Filings](/companies/ulbi/filings.md) · [Insiders](/companies/ulbi/insiders.md) Latest reported revenue: [$47.9m](/filings/0001437749-26-026432.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:Revenues, accession 0001437749-26-026432). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [35.7](/filings/0001437749-25-035475.md) | [43.9 d](/filings/0001437749-26-009385.md) | [50.7](/filings/0001437749-26-015750.md) | [48.6](/filings/0001437749-26-026432.md) | [43.4](/filings/0001437749-25-035475.md) | [48.5 d](/filings/0001437749-26-009385.md) | [47.4](/filings/0001437749-26-015750.md) | [47.9](/filings/0001437749-26-026432.md) | | Gross margin | % | [24.3%](/filings/0001437749-25-035475.md) | [24.2% d](/filings/0001437749-26-009385.md) | [25.1%](/filings/0001437749-26-015750.md) | [23.9%](/filings/0001437749-26-026432.md) | [22.2%](/filings/0001437749-25-035475.md) | [24.9% d](/filings/0001437749-26-009385.md) | [21.3%](/filings/0001437749-26-015750.md) | [28.9%](/filings/0001437749-26-026432.md) | | Operating margin | % | [1.4%](/filings/0001437749-25-035475.md) | [3.4% d](/filings/0001437749-26-009385.md) | [6.7%](/filings/0001437749-26-015750.md) | [4.6%](/filings/0001437749-26-026432.md) | [(2.2%)](/filings/0001437749-25-035475.md) | [(21.9%) d](/filings/0001437749-26-009385.md) | [(0.5%)](/filings/0001437749-26-015750.md) | [7.2%](/filings/0001437749-26-026432.md) | | Net margin | % | [0.7%](/filings/0001437749-25-035475.md) | [0.4% d](/filings/0001437749-26-009385.md) | [3.7%](/filings/0001437749-26-015750.md) | [1.8%](/filings/0001437749-26-026432.md) | [(2.8%)](/filings/0001437749-25-035475.md) | [(15.3%) d](/filings/0001437749-26-009385.md) | [(1.0%)](/filings/0001437749-26-015750.md) | [5.3%](/filings/0001437749-26-026432.md) | | Diluted EPS | $ per share | [0.02](/filings/0001437749-25-035475.md) | not reported | [11.00](/filings/0001437749-26-015750.md) | [5.00](/filings/0001437749-26-026432.md) | [(0.07)](/filings/0001437749-25-035475.md) | not reported | [(3.00)](/filings/0001437749-26-015750.md) | [15.00](/filings/0001437749-26-026432.md) | | Free cash flow | $m | [4.2 d](/filings/0001437749-25-035475.md) | [2.4 d](/filings/0001437749-26-009385.md) | [2.5](/filings/0001437749-26-015750.md) | [4.8 d](/filings/0001437749-26-026432.md) | [(0.8) d](/filings/0001437749-25-035475.md) | [0.6 d](/filings/0001437749-26-009385.md) | [1.5](/filings/0001437749-26-015750.md) | [0.7 d](/filings/0001437749-26-026432.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [98.3](/filings/0001437749-23-008694.md) | [132](/filings/0001437749-24-008872.md) | [159](/filings/0001437749-25-010360.md) | [164](/filings/0001437749-26-009385.md) | [191](/filings/0001437749-26-009385.md) | | Gross margin | % | [25.1%](/filings/0001437749-23-008694.md) | [22.3%](/filings/0001437749-24-008872.md) | [24.7%](/filings/0001437749-25-010360.md) | [25.7%](/filings/0001437749-26-009385.md) | [24.1%](/filings/0001437749-26-009385.md) | | Operating margin | % | [0.0%](/filings/0001437749-23-008694.md) | [0.1%](/filings/0001437749-24-008872.md) | [6.0%](/filings/0001437749-25-010360.md) | [6.1%](/filings/0001437749-26-009385.md) | [(3.1%)](/filings/0001437749-26-009385.md) | | Net margin | % | [(0.2%)](/filings/0001437749-23-008694.md) | [(0.1%)](/filings/0001437749-24-008872.md) | [4.5%](/filings/0001437749-25-010360.md) | [3.8%](/filings/0001437749-26-009385.md) | [(3.1%)](/filings/0001437749-26-009385.md) | | Diluted EPS | $ per share | [0.05](/filings/0001437749-23-008694.md) | [0.05](/filings/0001437749-24-008872.md) | [0.44](/filings/0001437749-25-010360.md) | [38.00](/filings/0001437749-26-009385.md) | [(35.00)](/filings/0001437749-26-009385.md) | | Free cash flow | $m | [1.5](/filings/0001437749-23-008694.md) | [(2.9)](/filings/0001437749-24-008872.md) | [(0.6)](/filings/0001437749-25-010360.md) | [14.7](/filings/0001437749-26-009385.md) | [7.1](/filings/0001437749-26-009385.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ulbi/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Visionary Wealth Advisors](/funds/1802984.md) | 2026-06-30 | $7.0m | 1,109,170 | | Added +3,016 | | [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $6.1m | 963,733 | | Reduced −31,113 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.9m | 464,730 | | Added +6,893 | | [Truffle Hound Capital, LLC](/funds/1595862.md) | 2026-06-30 | $1.6m | 250,000 | | Unchanged | | [RBF Capital, LLC](/funds/1134621.md) | 2026-06-30 | $1.4m | 218,714 | | Unchanged | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $1.1m | 171,790 | | Reduced −26,300 | | [Connor, Clark & Lunn Investment Management Ltd.](/funds/1596800.md) | 2026-06-30 | $979.9k | 155,043 | | Added +22 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $975.8k | 154,406 | | Added +8,133 | | [RAYMOND JAMES FINANCIAL INC](/funds/720005.md) | 2026-06-30 | $863.9k | 136,696 | | Reduced −2,637 | | [ARROWSTREET CAPITAL, LIMITED PARTNERSHIP](/funds/1164508.md) | 2026-06-30 | $801.1k | 126,753 | | Unchanged | ## Recent filings [All 777 filings](/companies/ulbi/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-29 | 16:23 ET | [SCHEDULE 13D/A](/filings/0000933430-26-000005.md) | Ownership report, active investor, amended | 0000933430-26-000005 | | 2026-10-28 | 12:13 ET | [8-K](/filings/0001437749-26-033731.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-033731 | | 2026-08-07 | 16:01 ET | [8-K](/filings/0001437749-26-026573.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-026573 | | 2026-08-07 | 07:30 ET | [10-Q](/filings/0001437749-26-026432.md) | Quarterly report, period 2026-06-30 | 0001437749-26-026432 | | 2026-07-23 | 16:27 ET | [8-K](/filings/0001437749-26-024330.md) | 5.07 Shareholder vote results | 0001437749-26-024330 | | 2026-06-02 | 13:07 ET | [DEF 14A](/filings/0001437749-26-019134.md) | Proxy statement, period 2026-07-22 | 0001437749-26-019134 | | 2026-05-08 | 07:31 ET | [10-Q](/filings/0001437749-26-015750.md) | Quarterly report, period 2026-03-31 | 0001437749-26-015750 | | 2026-05-08 | 07:30 ET | [8-K](/filings/0001437749-26-015749.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-015749 | | 2026-04-29 | 08:29 ET | [10-K/A](/filings/0001437749-26-013737.md) | Annual report, amended, period 2025-12-31 | 0001437749-26-013737 | | 2026-03-23 | 16:01 ET | [10-K](/filings/0001437749-26-009385.md) | Annual report, period 2025-12-31 | 0001437749-26-009385 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-009385.md), filed Mar 23, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/3d2afaa9-116d-4739-913a-43980b89f08f) ## About the filer - CIK: 875657 - Tickers: ULBI - Exchange: Nasdaq - SIC code: 3690 Miscellaneous Electrical Machinery, Equipment & Supplies - State of incorporation: DE - Filer category: Accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:24 ET. No prices; not investment advice.